LAMP1-mediated Immunometabolic Characteristics in Alzheimer Disease and Mild Cognitive Impairment: A Transcriptomic Profiling Study across Multiple GEO Datasets
,
Abstract
This study characterized lysosome-associated membrane protein 1 (LAMP1)-related immunometabolic abnormalities in Alzheimer disease (AD) and mild cognitive impairment (MCI) using peripheral blood transcriptomic data from three GEO cohorts (GSE63060, GSE63061, and GSE140829).
After preprocessing and cross-cohort integration, directionally consistent LAMP1-related genes were identified, and a composite index comprising ITGAM, ITGB2, LAMP1, and GBA was constructed. Analyses included correlation, group comparison, ROC analysis, random-effects meta-analysis, and leave-one-out validation.A total of 1262 samples were included.
LAMP1 was consistently elevated in AD and MCI versus controls, with pooled effect sizes of Hedges’ g=0.330 and 0.514, respectively. Immune-, lysosome-, and metabolism-related genes, including ITGAM, ITGB2, GBA, GNS, RXRA, G6PD, and TCIRG1, showed concordant changes across both conditions. The 4-gene index was also increased in AD and MCI (g= 0.543 and 0.648), and LAMP1 strongly correlated with the 3-gene index excluding itself (r=0.760).
These findings suggest reproducible peripheral blood transcriptomic alterations related to immune activation, lysosomal dysfunction, and metabolic regulation in AD and MCI. As this was a secondary analysis of public datasets without adjustment for blood-cell composition, the results should be interpreted as exploratory molecular signals rather than definitive diagnostic biomarkers.
2. Xiaopeng Z, Jing Y, Xia L, Xingsheng W, Juan D, Yan L, et al. Global burden of Alzheimer's disease and other dementias in adults aged 65 years and older, 1991-2021: population-based study. Front Public Health. 2025;13:1585711.
3. Petersen RC. Mild cognitive impairment. Continuum (Minneapolis, Minn.). 2016;22(2 Dementia):404-18.
4. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119(4):252-65.
5. Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q. Alzheimer's disease: epidemiology and clinical progression. Neurol Ther. 2022;11(2):553-69.
6. Iwatsubo T, Sperling RA, Algeciras-Schimnich A, Arai H, Barron AM, Benzinger TLS, et al. Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives. Alzheimers Dement. 2025;21(8):e70536.
7. Rahimpour S, Clary BL, Nasoohi S, Berhanu YS, Brown CM. Immunometabolism in brain aging and neurodegeneration: bridging metabolic pathways and immune responses. Aging Dis. 2024;16(6):3361-80.
8. Jung ES, Choi H, Mook-Jung I. Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research. Mol Neurodegener. 2025;20(1):37.
9. Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med. 2022;14(1):e14408.
10. Zhong H, Zhou X, Uhm H, Jiang Y, Cao H, Chen Y, et al. Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification. Alzheimers Dement. 2024;20(4):2469-84.
11. Iga JI, Yoshino Y, Ozaki T, Tachibana A, Kumon H, Funahashi Y, et al. Blood RNA transcripts show changes in inflammation and lipid metabolism in Alzheimer's disease and mitochondrial function in mild cognitive impairment. J Alzheimers Dis Rep. 2024;8(1):1690-703.
12. Shvetcov A, Thomson S, Spathos J, Cho AN, Wilkins HM, Andrews SJ, et al. Blood-based transcriptomic biomarkers are predictive of neurodegeneration rather than Alzheimer's disease. Int J Mol Sci. 2023;24(19):15011.
13. Song L, Yang YT, Guo Q, ZIB C, Zhao XM. Cellular transcriptional alterations of peripheral blood in Alzheimer's disease. BMC Med. 2022;20(1):266.
14. Krzewski K, Gil-Krzewska A, Nguyen V, Peruzzi G, Coligan JE. LAMP1/CD107a is required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity. Blood. 2013;121(23):4672-83.
15. Barrachina M, Maes T, Buesa C, Ferrer I. Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer's disease. Neuropath Appl Neuro. 2006;32(5):505-16.
16. Zhang W, Xu C, Sun J, Shen HM, Wang J, Yang C. Impairment of the autophagy-lysosomal pathway in Alzheimer's diseases: pathogenic mechanisms and therapeutic potential. Acta Pharm Sin B. 2022;12(3):1019-40.
17. Sood S, Gallagher IJ, Lunnon K, Rullman E, Keohane A, Crossland H, et al. A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status. Genome Biol. 2015;16(1):185.
18. Lopez LM, Harris SE, Luciano M, et al. Evolutionary conserved longevity genes and human cognitive abilities in elderly cohorts. Eur J Hum Genet. 2012;20(3):341-7.
19. Nixon RA, Rubinsztein DC. Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases. Nature Reviews. Mol Cell Biol. 2024;25(11):926-46.
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| Alzheimer disease GEO database LAMP1 Mild cognitive impairment Peripheral blood transcriptome Related molecular features | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
